Iterum Therapeutics Plc’s filing revealed that its Director Dunne Michael W. acquired Company’s shares for reported $10854.0 on Aug 08 ’25. In the deal valued at $0.72 per share,15,000 shares were bought. As a result of this transaction, Dunne Michael W. now holds 235,001 shares worth roughly $0.18 million.
Gabelli & Co upgraded its Iterum Therapeutics Plc [ITRM] rating to a Hold from a a Sell in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in mid March from “a Neutral” to “a Buy”. RBC Capital Mkts also remained covering ITRM and has decreased its forecast on June 02, 2020 with a “Sector perform” recommendation from previously “an Outperform” rating. Gabelli & Co revised its rating on January 21, 2020. It rated ITRM as “a Sell” which previously was an “a Buy”.
Price Performance Review of ITRM
On Tuesday, Iterum Therapeutics Plc [NASDAQ:ITRM] saw its stock jump 8.23% to $0.77. Over the last five days, the stock has gained 11.16%. Iterum Therapeutics Plc shares have fallen nearly -29.73% since the year began. Nevertheless, the stocks have fallen -56.33% over the past one year. While a 52-week high of $3.02 was reached on 01/06/25, a 52-week low of $0.66 was recorded on 08/06/25.
Levels Of Support And Resistance For ITRM Stock
The 24-hour chart illustrates a support level at 0.7394, which if violated will result in even more drops to 0.7058. On the upside, there is a resistance level at 0.7970. A further resistance level may holdings at 0.8210.
How much short interest is there in Iterum Therapeutics Plc?
A steep rise in short interest was recorded in Iterum Therapeutics Plc stocks on 2025-07-31, growing by 0.89 million shares to a total of 2.08 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 1.19 million shares. There was a rise of 42.93%, which implies that there is a positive sentiment for the stock.
